GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ligand Pharmaceuticals Inc (STU:LGDN) » Definitions » Cyclically Adjusted PS Ratio

Ligand Pharmaceuticals (STU:LGDN) Cyclically Adjusted PS Ratio : 10.92 (As of Sep. 21, 2024)


View and export this data going back to 2013. Start your Free Trial

What is Ligand Pharmaceuticals Cyclically Adjusted PS Ratio?

As of today (2024-09-21), Ligand Pharmaceuticals's current share price is €91.50. Ligand Pharmaceuticals's Cyclically Adjusted Revenue per Share for the quarter that ended in Jun. 2024 was €8.38. Ligand Pharmaceuticals's Cyclically Adjusted PS Ratio for today is 10.92.

The historical rank and industry rank for Ligand Pharmaceuticals's Cyclically Adjusted PS Ratio or its related term are showing as below:

STU:LGDN' s Cyclically Adjusted PS Ratio Range Over the Past 10 Years
Min: 5.59   Med: 16.25   Max: 62.95
Current: 11.01

During the past years, Ligand Pharmaceuticals's highest Cyclically Adjusted PS Ratio was 62.95. The lowest was 5.59. And the median was 16.25.

STU:LGDN's Cyclically Adjusted PS Ratio is ranked worse than
70.91% of 464 companies
in the Biotechnology industry
Industry Median: 5.355 vs STU:LGDN: 11.01

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Ligand Pharmaceuticals's adjusted revenue per share data for the three months ended in Jun. 2024 was €2.140. Add all the adjusted revenue per share for the past 10 years together and divide 10 will get our Cyclically Adjusted Revenue per Share, which is €8.38 for the trailing ten years ended in Jun. 2024.

Shiller PE for Stocks: The True Measure of Stock Valuation


Ligand Pharmaceuticals Cyclically Adjusted PS Ratio Historical Data

The historical data trend for Ligand Pharmaceuticals's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ligand Pharmaceuticals Cyclically Adjusted PS Ratio Chart

Ligand Pharmaceuticals Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 15.13 11.97 14.18 8.16 8.02

Ligand Pharmaceuticals Quarterly Data
Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 8.31 6.76 8.02 8.00 9.01

Competitive Comparison of Ligand Pharmaceuticals's Cyclically Adjusted PS Ratio

For the Biotechnology subindustry, Ligand Pharmaceuticals's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Ligand Pharmaceuticals's Cyclically Adjusted PS Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Ligand Pharmaceuticals's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Ligand Pharmaceuticals's Cyclically Adjusted PS Ratio falls into.



Ligand Pharmaceuticals Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

Ligand Pharmaceuticals's Cyclically Adjusted PS Ratio for today is calculated as

Cyclically Adjusted PS Ratio=Share Price/ Cyclically Adjusted Revenue per Share
=91.50/8.38
=10.92

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Ligand Pharmaceuticals's Cyclically Adjusted Revenue per Share for the quarter that ended in Jun. 2024 is calculated as:

For example, Ligand Pharmaceuticals's adjusted Revenue per Share data for the three months ended in Jun. 2024 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Jun. 2024 (Change)*Current CPI (Jun. 2024)
=2.14/132.5538*132.5538
=2.140

Current CPI (Jun. 2024) = 132.5538.

Ligand Pharmaceuticals Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201409 0.544 100.428 0.718
201412 0.895 99.070 1.197
201503 0.654 99.621 0.870
201506 0.771 100.684 1.015
201509 0.735 100.392 0.970
201512 0.903 99.792 1.199
201603 1.195 100.470 1.577
201606 0.834 101.688 1.087
201609 0.838 101.861 1.091
201612 1.732 101.863 2.254
201703 1.189 102.862 1.532
201706 1.073 103.349 1.376
201709 1.189 104.136 1.513
201712 1.767 104.011 2.252
201803 1.836 105.290 2.311
201806 3.154 106.317 3.932
201809 1.627 106.507 2.025
201812 2.280 105.998 2.851
201903 1.809 107.251 2.236
201906 1.131 108.070 1.387
201909 1.200 108.329 1.468
201912 1.352 108.420 1.653
202003 1.816 108.902 2.210
202006 2.203 108.767 2.685
202009 2.209 109.815 2.666
202012 2.079 109.897 2.508
202103 2.686 111.754 3.186
202106 4.093 114.631 4.733
202109 3.215 115.734 3.682
202112 1.874 117.630 2.112
202203 1.971 121.301 2.154
202206 2.780 125.017 2.948
202209 3.491 125.227 3.695
202212 2.816 125.222 2.981
202303 2.285 127.348 2.378
202306 1.373 128.729 1.414
202309 1.772 129.860 1.809
202312 1.458 129.419 1.493
202403 1.573 131.776 1.582
202406 2.140 132.554 2.140

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Ligand Pharmaceuticals  (STU:LGDN) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


Ligand Pharmaceuticals Cyclically Adjusted PS Ratio Related Terms

Thank you for viewing the detailed overview of Ligand Pharmaceuticals's Cyclically Adjusted PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Ligand Pharmaceuticals Business Description

Traded in Other Exchanges
Address
3911 Sorrento Valley Boulevard, Suite 110, San Diego, CA, USA, 92121
Ligand Pharmaceuticals Inc is a biopharmaceutical company focused on developing and acquiring technologies that aid in creating medicine. The company has partnerships and license agreements with various pharmaceutical and biotechnology companies. Ligand's business model is based on drug discovery, early-stage drug development, product reformulation, and partnerships. The company's revenue consists of three primary elements: royalties from commercialized products, license and milestone payments, and sale of its trademarked Captisol material.

Ligand Pharmaceuticals Headlines

No Headlines